Most Recent Articles by Steve Duffy
The Company stated that they plan to begin a Phase 2 trial of AXS-12 before the end of 2018, with results anticipated for the first half of 2019.
Tiglutik is supplied as a thickened riluzole liquid that is intended to ease administration for patients with dysphagia.
The treatment is currently being evaluated in a Phase 2 study (ELEVATE) in patients with major depressive disorder who have had an inadequate response to standard antidepressant therapy.
Safety data for Fycompa was consistent with the safety profile in adult populations without the need for weight-based dosing.
As part of the REMS program, drug companies with approved opioid analgesics must make training available to prescribers and provide unrestricted grants to accredited continuing education providers for the development of education courses.
More Articles by Steve Duffy
Neurology Advisor Articles
- New Diagnostic Criteria for Neurosarcoidosis: What You Need to Know
- Guideline for Diagnosis and Treatment of Idiopathic Intracranial Hypertension
- Guidelines on the Use of OnabotulinumtoxinA for Chronic Migraine
- Ivy League Rule Change Linked to Fewer Concussions During NCAA Football Games
- Addressing Levodopa-Resistant Parkinson Disease
- High Daily Stress Linked to Migraine Prevalence in Women
- Researchers Identify Coffee Component That May Provide Neuroprotection
- Functional Imaging in Movement Disorders: Diagnostic Advantages
- Dextroamphetamine Plus Physical Therapy Nonsuperior to Placebo for Improving Post-Stroke Motor Recovery
- Nusinersen May Be Effective for Short-Term Motor Function Improvements in Spinal Muscular Atrophy